Jiangsu Hengrui Pharma launched a new global company, Luzsana Biotechnology, devoted to making its most advanced medications available and affordable in global markets. For 25 years, Hengrui has been developing novel drugs, with a portfolio of 250 ...
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

 


Featured Event:
ChinaBio® Partnering Forum 2022
Beijing and Digital
September 13–16, 2022
 
ChinaBio® Partnering Forum is the largest and most productive life science partnering event in China. To be held as a 4-day hybrid event; 2 days in-person, 2 days virtually,September 13–16, 2022, the conference will bring together biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for four days of successful partnering. ChinaBio® Partnering Forum 2021 attracted 1,000+ delegates from over 500 companies and 27 countries, making it a must-attend global event for companies interested in developing cross-border partnerships, both inside and outside of China. In addition to partnering meetings, the event will feature a blend of live and on-demand program sessions, company presentations, table-top exhibits, company showcases, and networking sessions.
Register before April 2 to save USD100 on your registration.

ChinaBio® Weekly Update

Contents


Hengrui Launches Luzsana to Bring its Novel Medications to Global Markets

Written by Richard Daverman, PhD.

Jiangsu Hengrui Pharma launched a new global company, Luzsana Biotechnology, devoted to making its most advanced medications available and affordable in global markets. For 25 years, Hengrui has been developing novel drugs, with a portfolio of 250 clinical studies for unmet needs in oncology, cardiovascular, metabolic/diabetes, pain management, immunology and liver/renal disease. Initially, the company will co-develop 11 of Hengrui’s candidates that range from preclinical to Phase III stage. All the candidates have first-in-class or best-in-class potential, the company said. Luzsana is headquartered in Princeton, NJ with facilities in Basel and Tokyo. More details....

Stock Symbol: (SHA: 600275)

Share this with colleagues:  

    
 

Laekna Raises $61 Million for its 14-Drug Cancer/Liver Disease Portfolio

Written by Richard Daverman, PhD.

Shanghai Laekna Therapeutics raised $61 million in a Series D financing for its next-gen cancer and liver disease medicines. Founded in 2017, the company has built a portfolio that consists of 14 novel drug candidates, including six clinical programs, three of which are multi-regional clinical trials (including one pivotal trial). Laekna has acquired at least four drug candidates from Novartis: an androgen inhibitor in 2017; two Akt inhibitors in 2018; and an anti-PD-1 antibody in 2020.  The company’s latest funding was led by CS Capital and joined by Worldstar and Infinity Capital. More details...,

Share this with colleagues:  

    
 

Kelun Out-Licenses Global Rights for Candidate to Merck/MSD in $1.4 Billion Deal

Written by Richard Daverman, PhD.

Sichuan Kelun Pharmaceutical out-licensed global rights (ex-China) for a large molecule candidate to Merck in a deal worth nearly $1.4 billion. Kelun will receive $47 million in upfront payments and up to $1.36 billion in milestones. Although the candidate was not identified, it is expected to be SKB264, a third-gen TROP2-targeting antibody-drug conjugate in Phase II trials in the US and China. The candidate is being developed by KLUS Pharma, Kelun’s New Jersey-based novel drug developing subsidiary. Merck is known as MSD outside of North America. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:  

    
 

Henlius Out-licenses Latin American Rights for Three Biosimilars in $55 Million Deal

Written by Richard Daverman, PhD.

Shanghai Henlius Biotech signed a $55 million agreement to out-license rights for three biosimilar drugs in 16 Latin America countries to Eurofarma, a Brazil pharma. Eurofarma will have rights to market the three biosimilars to drugs that were originally developed by Genentech: Rituxan (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab). Previously, Henlius had out-licensed rights to some of the drugs in other South American countries, as it has for major markets around the world. Henlius develops biosimilars, bio-betters and novel biologic candidates. More details....

Stock Symbol: (HK: 2696)

Share this with colleagues:  

    
 

Green Valley Stops Global Phase III Trial of its Novel China-Approved Alzheimer’s Drug

Written by Richard Daverman, PhD.

Green Valley Pharmaceuticals has stopped the international Phase III trial for its Alzheimer’s disease treatment, citing difficulties caused by COVID and the current “funding winter” of raising capital. Green Valley’s Alzheimer’s therapy was granted a surprise China approval in 2019, the first new AD treatment in 16 years. GV-971, a product derived from seaweed, has a unique mechanism that targeted gut biota to prevent the buildup of amyloid/tau related tangles in the brain. Following China approval, Green Valley started a global five-year Phase III  trial in over 2,000 people to internationalize its novel therapy. More details....

Share this with colleagues:  

    
 

More Recent Articles

Written by Richard Daverman, PhD.


 Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC